Clinical Trial
Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2)
Affiliations
- PMID: 17935281
Item in Clipboard
Clinical Trial
Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2)
J BUON.
2007 Sep.
Abstract
Vaccines are well known in the context of prevention of diseases caused by infectious agents. Current research is now aimed at using vaccines to manipulate the immune system to eliminate established diseases, including cancer. Several such immunotherapeutic vaccines are now in clinical trials and are beginning to show clinical benefit. TG4010 is one such vaccine. It incorporates the MUC1 antigen, which is overexpressed in the majority of cancers, into a non-propagative pox viral vector, MVA. A second gene, interleukin-2 is also incorporated into TG4010 as an immune stimulus. The vaccine has been tested in breast, kidney, prostate and lung cancers with encouraging results.
Similar articles
-
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.J Gene Med. 2003 Aug;5(8):690-9. doi: 10.1002/jgm.397. J Gene Med. 2003. PMID: 12898638 Clinical Trial.
-
Technology evaluation: TG-1031, Transgene SA.Curr Opin Mol Ther. 2000 Feb;2(1):106-11. Curr Opin Mol Ther. 2000. PMID: 11249647 Review.
-
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.J Thorac Oncol. 2008 Jul;3(7):735-44. doi: 10.1097/JTO.0b013e31817c6b4f. J Thorac Oncol. 2008. PMID: 18594319 Clinical Trial.
-
Tecemotide: an antigen-specific cancer immunotherapy.Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836. Hum Vaccin Immunother. 2014. PMID: 25483673 Free PMC article. Review.
-
MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.Expert Opin Biol Ther. 2010 Jul;10(7):1037-48. doi: 10.1517/14712598.2010.485185. Expert Opin Biol Ther. 2010. PMID: 20420512 Review.
Cited by
-
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Cancer Biol Ther. 2014 Sep;15(9):1226-38. doi: 10.4161/cbt.29686. Epub 2014 Jun 27. Cancer Biol Ther. 2014. PMID: 24971746 Free PMC article.
-
Management of breast cancer by vaccine: fact or fiction.J IMA. 2013 Apr 22;44(1):44-1-9055. doi: 10.5915/44-1-9055. Print 2012. J IMA. 2013. PMID: 23864997 Free PMC article.
-
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.Vaccine. 2010 Feb 10;28(6):1547-57. doi: 10.1016/j.vaccine.2009.11.056. Epub 2009 Dec 5. Vaccine. 2010. PMID: 19969118 Free PMC article.
-
State of the art in tumor antigen and biomarker discovery.Cancers (Basel). 2011 Jun 9;3(2):2554-96. doi: 10.3390/cancers3022554. Cancers (Basel). 2011. PMID: 24212823 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous